Brought to you by 
Vanguard Medica develops Roche's endothelin antagonist
29 Mar 2011
Executive Summary
Vanguard Medica will develop Ro 61-1790, Roche's endothelin antagonist compound for acute renal failure (ARF) prevention and sub-arachnoid hemorrhage (SAH). Roche completed preclinical and Phase I trials on the compound, renamed VML 588 by Vanguard.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vanguard Medica develops Roche's endothelin antagonist
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice